Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach

NCT04690920 is registered in ClinicalTrials.gov with University of Lahore as lead sponsor.

NCT NCT04690920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04690920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach
Lead sponsor
University of Lahore
Phase
Not applicable
Overall status
Completed
Start date
July 23, 2020
Completion date
December 10, 2020
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus disease 2019 (covid-19)